The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To see volume remaining after months of it being so quiet.. We are certainly on more peoples radar now
At least porky didn't erase his posting history and reinvent himself after DDDD , unlike a certain poster who did that after DMTR
Cannot get a quote at 2p to buy
The 1,99 at 50k is a buy from price quote ,sp at D 8ema and W 21 ema buys need to confirm PB at support here
Thankyou for this msuk
Today i am mostly a deflator.
You are funny, have you just learnt the word “pump”, check my last post on Pyc to know if that’s what I’m doing
Made 3 attempts tp break the 2.30 bid ,seems still to be bullish ,possible 2.1 now to be a new support
https://invst.ly/11d743
Thank you Mr P for your reply.
I do not have the luxury of having L2.
Maybe a P&D has gone incognito now, as before, you could see it, esp on X with rockets, and flash cars emojis everywhere, now there is nothing.
You are right thou, a TR1 from a new II etc would show great confidence.
I sincerely hope you and S4 are wrong on this potential placing.
From now on, i will just post things on the way i see them, any relevant info ( the way i see it ) etc.
I am not going to get involved in any personal or quasi negativity.
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug’s development by as much as $242 million, from the current estimate of around $800 million. Physiomics develops computational systems biology models to predict and understand cancer drug
Well said Acker
Quite why people spend 2 yrs on here and VAL spreading lies and mistaken opinions is beyond me
Every share on the AIMS market gets "pumped and dumped" at some time, it is the very nature of the beast.
Certain shares attract P & D traders more than others, Prem is a classic example.
One has to factor in such circumstances when considering an investment and yes, we have all fallen victim over the years.
Games will be played with PYC stock however IMO the company has a product that is in demand and has a future in the marketplace.
Like nearly every other company cash flow can be a barrier ,AIMS is here to help and is probably the main function of listing here.
I am comfortable with my investment .
Acker
Please find something else to do with your time Porky
Why DID you end up not doing due diligence on DDDD and losing everything ?
You see that post from @Hepran is a beautiful example of a pump post just pre market open but if it can help some 1p holders exit at good gains they can come back in at the next placing or on the fall back.
Pump Punters run the risk of taking a beating this time which is rather funny to watch but that's the name of the game.
Reversal from bottom yesterday , up 32% with little volume which shows what could happen if the volume increases which it should, I’m hoping we can break 3p in this second wave.
@Kidlington
Because you have traders like @TrickyEFC posting to pump and you can see the trade activity on L2
At the end of the day its a positive as the more penny holders you flush out at 100% gain the better but they are doing this now pre the annual results statement due end of the month for a reason and that's because we already know it wont make great reading.
Ideally what PYC need is a TR1 from an II or Investment house to take a chunk of stock and it remain in sticky hands. Its currently just punt money. Whilst you cant predict a share price my view is this will settle back towards the penny again until they deliver proof they can at least reach break even then place again at 1p.
The BE point as long as costs don't increase further is Revenue of £1.260,000. The results end of this month should confirm Revenue of £670,000 and with the recent placing money about £500k cash and cash equivalents left at end of last June.
They must diversify and the new COO Peter IMO can help with this. Everyone has an opinion but if i had taken this role, i would settle in, start getting my ducks in a row, look at some bolt on services they can diversify into and raise about £500k in the new year/first quarter to support the transition support the placing and issue myself a load of options on success.
If you are a LTH here you will need to wait that bit longer as i see it but my call is Jim will have no option but to do a further raise because they need to win too much business now to get to break even and it will take longer and even if they win contracts they need the working capital to support cash flow and he needs cash to diversify.
This is why I'm saying its just P&D cash, if you evaluate it you would support next placing soon, probably at a 1p again if Peter can deliver a plan to take the business forwards, I believe you and Laura2022 will get your day in the sun it will just take a bit longer.
They are UK L, but i am shocked you did not know that.
Thanks for the update on Cellcentric
Are they UK or USA please ?
Yes, a nice day.
Porky, i know you are more versed in all thinks stockmarket than me, but where is the evidence of a P&D?
Unless that scenario has changed over the last few years, i see no ramping on X, there is only a few commenting on it (namely moi), there has only been 36 posts here all day, and no sign of Ria and their every minute commentary. There is next to nothing on Telegram.
Where is the evidence?
Today, Cellcentric, who we did a collaboration on CCS1477 ( Inobrodib ) with, announced a $3M cash injection from BrightEdge who are affiliated with AmericanCancer.
This is on top of the $25m from Pfizer some weeks ago.
Recently invested here (August) and resisted the temptation to sell as it took off. Like what I see. Tricky ?? I was lucky enough to meet Trevor years ago and he was a lovely, lovely guy as was his girlfriend. Assuming I interpret your name tag correctly ??
Ackers
Good morning Ackers
Sorry for later reply
Excellent summary of the potential spending that cone to PYC from long established clients, for confidentiality PYC often aren't allowed to day much but the recent contract used the word "SUBSTANTIAL: which clearly shows q step change from usual .
PYC have recently had new collabs from Bicycle, who raised appox $240m.
They helped with Cellcentric with CCS1477 ( now inobrodib )and they have just raised approx $20m and had fast track orphan status from FDA.
Numab secured $110m funding in 2021.
You could hope that a fraction of those $ or £ raised ( at least ) could come PYC's way to help with projects either already started or in the future from these companies?
Then there is the £6m from VAL for (201) as shown in Feb 2021 RNS ( still not a certainly of course but VAL CEO says still by end of 2023 for deal)
A42B4C4...........LIAR!
The company is gaining creditability amongst its peers.
Further contracts will only enhance this.
Acker